Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2015.1075020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome.
Invest New Drugs
October 2022
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Knowledge of dasatinib-induced nephrotic syndrome is largely based on case reports. The clinical features of dasatinib-induced nephrotic syndrome are unknown. We collected case reports of 25 patients with nephrotic syndrome and analyzed their clinical characteristics.
View Article and Find Full Text PDFDasatinib-Induced Nephrotic Syndrome: A Case Report.
Cureus
December 2021
Hematology and Medical Oncology, NMC Royal Hospital, Sharjah, ARE.
Second-generation tyrosine kinase inhibitors (TKI), such as nilotinib and dasatinib, are used in the first-line treatment of chronic myeloid leukemia (CML), usually after the failure or resistance to imatinib. Despite a good safety profile, medications in this category have an increased incidence of specific adverse events such as pulmonary hypertension, pleural effusion, and cardiovascular/peripheral arterial events. However, renal complications are rarely reported and observed.
View Article and Find Full Text PDFA case of dasatinib-induced focal segmental glomerulosclerosis in a patient with Philadelphia chromosome positive chronic myeloid leukemia.
Nephrol Ther
February 2021
Health Sciences University, Umraniye training and research hospital clinic of Internal Medicine, Istanbul, Turkey.
Focal segmental glomerulosclerosis is a common glomerular histological lesion, which is usually characterised by non-nephrotic range proteinuria or nephrotic syndrome. It may be idiopathic or occurs secondarily to drugs, diabetes, obesity or HIV nephropathy and other infections. Dasatinib, a tyrosine kinase inhibitor that has been used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia, has a few renal adverse effects.
View Article and Find Full Text PDFDasatinib-induced nephrotic syndrome: a case of phenoconversion.
Croat Med J
June 2019
Inga Mandac Rogulj, Department of hematology, Clinical Hospital Merkur, Zajčeva Street 19, 10000 Zagreb, Croatia,
We present the case of a 33-year-old chronic myeloid leukemia (CML) female patient, in whom the occurrence of nephrotic syndrome, during the treatment with tyrosine kinase activity inhibitors (TKIs), was potentially influenced by transient phenoconversion. Seven years after the CML diagnosis in 2004 and complete response, the patient experienced pain in the mandible and extremities. After this, imatinib was replaced by nilotinib, but generalized maculopapular rash was presented and successfully treated with antihistamines.
View Article and Find Full Text PDFDasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report.
BMC Nephrol
March 2019
Dialysis Division, University of Miyazaki Hospital, Miyazaki, Japan.
Background: Dasatinib is a second-generation tyrosine kinase inhibitor that is indicated for the treatment of patients with chronic myeloid leukemia. Here, we report the case of a man with nephrotic syndrome that was caused by dasatinib.
Case Presentation: A 40-year-old man with chronic myeloid leukemia was referred to our hospital because of proteinuria 1 month after dasatinib therapy was introduced.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!